-
公开(公告)号：WO2010039852A2
公开(公告)日：2010-04-08
申请号：PCT/US2009059059
申请日：2009-09-30
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , KUTSKOVA YULIYA A , MEMMOTT JOHN E
Inventor： HSIEH CHUNG-MING , KUTSKOVA YULIYA A , MEMMOTT JOHN E
CPC classification number: C40B50/06 , C07K16/00 , C07K16/1018 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/622 , C12Q2563/185 , C40B40/08
Abstract: The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.
Abstract translation: 本发明的特征在于改进的体外RNA显示文库以允许来自表达文库的scFv抗体分子的可靠表达和选择。 本发明的scFv抗体文库含有改善表达scFv抗体表达的优化的缩短的域间连接体。 scFv抗体文库还包括允许识别单个文库克隆，文库或其子集的短核酸条形码。 还提供了用于产生，扩增和分光本发明的scFv抗体文库的引物。
-
公开(公告)号：WO2010039850A1
公开(公告)日：2010-04-08
申请号：PCT/US2009/059057
申请日：2009-09-30
Applicant: ABBOTT LABORATORIES , HSIEH, Chung-ming , KUTSKOVA, Yuliya, A. , MEMMOTT, John, E.
Inventor： HSIEH, Chung-ming , KUTSKOVA, Yuliya, A. , MEMMOTT, John, E.
IPC: G01N33/53
CPC classification number: G01N33/54326 , C12N15/1041
Abstract: The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
Abstract translation: 本发明的特征在于体外RNA显示的改进方法，以允许来自表达文库的scFv抗体分子的可靠表达和选择。 改进的方法部分地涉及使用轻度还原条件，其有利于scFv链内二硫键，从而正确折叠scFv抗体分子。 尽管特别适合于scFv抗体分子的表达和选择，本发明的方法也适用于所有类别的蛋白质的体外RNA显示。
-
公开(公告)号：WO2008082651A2
公开(公告)日：2008-07-10
申请号：PCT/US2007026482
申请日：2007-12-28
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , ROGUSKA MICHAEL , TOMLINSON IAN , TUNA MIHRIBAN , GRANT STEVEN , ENEVER CARRIE
Inventor： HSIEH CHUNG-MING , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , ROGUSKA MICHAEL , TOMLINSON IAN , TUNA MIHRIBAN , GRANT STEVEN , ENEVER CARRIE
IPC: C07K16/24
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , C07K16/245 , C07K2317/569 , C07K2317/92
Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l a and human IL-I ß. The dual specific antibodies of the invention also neutralize both human IL-I a and human IC-I ß. The invention also provides domain antibodies (dAbs) specific for human IL-l a and human IL-l ß.
Abstract translation: 本发明提供了对人IL-1α和人IL-1β特异的分离的双重特异性抗体或其抗原结合部分。 本发明的双重特异性抗体还中和人IL-1α和人IC-1β。 本发明还提供对人IL-1α和人IL-1β特异性的结构域抗体（dAb）。
-
公开(公告)号：WO2010102251A3
公开(公告)日：2010-11-25
申请号：PCT/US2010026424
申请日：2010-03-05
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , HUGUNIN MARGARET , MURTAZA ANWAR , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , PEREZ JENNIFER M , ZHONG SUJU , TARCSA EDIT , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H , LEDDY MARY R
Inventor： HSIEH CHUNG-MING , HUGUNIN MARGARET , MURTAZA ANWAR , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , PEREZ JENNIFER M , ZHONG SUJU , TARCSA EDIT , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H , LEDDY MARY R
IPC: A61K39/395
CPC classification number: C07K16/468 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2300/00 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/50 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92
Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
Abstract translation: 描述了结合IL-17和/或IL-17F的蛋白以及其在用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法中的应用。
-
公开(公告)号：WO2010039852A3
公开(公告)日：2010-04-08
申请号：PCT/US2009/059059
申请日：2009-09-30
Applicant: ABBOTT LABORATORIES , HSIEH, Chung-Ming , KUTSKOVA, Yuliya, A. , MEMMOTT, John, E.
Inventor： HSIEH, Chung-Ming , KUTSKOVA, Yuliya, A. , MEMMOTT, John, E.
Abstract: The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.
-
Patent Agency Ranking
公开(公告)号：WO2013063114A1
公开(公告)日：2013-05-02
申请号：PCT/US2012/061690
申请日：2012-10-24
Applicant: ABBVIE INC. , HSIEH, Chung-ming , GHAYUR, Tariq , BENATUIL, Lorenzo , KUTSKOVA, Yuliya , MEMMOTT, John , PEREZ, Jeniffer , ZHONG, Suju , GOODRAEU, Carrie , CLABBERS, Anca
Inventor： HSIEH, Chung-ming , GHAYUR, Tariq , BENATUIL, Lorenzo , KUTSKOVA, Yuliya , MEMMOTT, John , PEREZ, Jeniffer , ZHONG, Suju , GOODRAEU, Carrie , CLABBERS, Anca
CPC classification number: C07K16/241 , A61K39/3955 , A61K45/06 , A61K47/6847 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-a), e.g., human TNF-a, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
Abstract translation: 公开了与肿瘤坏死因子-α（TNF-α）结合的分离的结合蛋白，例如其抗体结合部分，例如人TNF-α，以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。
-
公开(公告)号：WO2011025964A3
公开(公告)日：2011-04-21
申请号：PCT/US2010047006
申请日：2010-08-27
Applicant: ABBOTT LAB , BENATUIL LORENZO , BOGHAERT ERWIN R , GU JIJIE , HARRIS MARIA , HICKSON JONATHAN A , HSIEH CHUNG-MING , KUTSKOVA YULIYA , LI YINGCHUN , LIU ZHIHONG , MORGAN-LAPPE SUSAN
Inventor： BENATUIL LORENZO , BOGHAERT ERWIN R , GU JIJIE , HARRIS MARIA , HICKSON JONATHAN A , HSIEH CHUNG-MING , KUTSKOVA YULIYA , LI YINGCHUN , LIU ZHIHONG , MORGAN-LAPPE SUSAN
IPC: C07K16/28
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：WO2010102251A2
公开(公告)日：2010-09-10
申请号：PCT/US2010/026424
申请日：2010-03-05
Applicant: ABBOTT LABORATORIES , HSIEH, Chung-Ming , HUGUNIN, Margaret , MURTAZA, Anwar , McRAE, Bradford, L. , KUTSKOVA, Yuliya , MEMMOTT, John, E. , PEREZ, Jennifer, M. , ZHONG, Suju , TARCSA, Edit , CLABBERS, Anca , WALLACE, Craig , BRYANT, Shaughn, H. , LEDDY, Mary, R.
Inventor： HSIEH, Chung-Ming , HUGUNIN, Margaret , MURTAZA, Anwar , McRAE, Bradford, L. , KUTSKOVA, Yuliya , MEMMOTT, John, E. , PEREZ, Jennifer, M. , ZHONG, Suju , TARCSA, Edit , CLABBERS, Anca , WALLACE, Craig , BRYANT, Shaughn, H. , LEDDY, Mary, R.
IPC: A61K39/395
CPC classification number: C07K16/468 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2300/00 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/50 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , Y02A50/386 , Y02A50/41 , Y02A50/412 , Y02A50/466
Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
Abstract translation: 与用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法一起描述了结合IL-17和/或IL-17F的蛋白质。
-
公开(公告)号：WO2013063114A8
公开(公告)日：2014-03-20
申请号：PCT/US2012061690
申请日：2012-10-24
Applicant: ABBVIE INC , HSIEH CHUNG-MING , BENATUIL LORENZO , KUTSKOVA YULIYA , MEMMOTT JOHN , PEREZ JENNIFER , ZHONG SUJU , GOODREAU CARRIE , CLABBERS ANCA
Inventor： HSIEH CHUNG-MING , BENATUIL LORENZO , KUTSKOVA YULIYA , MEMMOTT JOHN , PEREZ JENNIFER , ZHONG SUJU , GOODREAU CARRIE , CLABBERS ANCA
CPC classification number: C07K16/241 , A61K39/3955 , A61K45/06 , A61K47/6847 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-a), e.g., human TNF-a, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
Abstract translation: 公开了与肿瘤坏死因子-α（TNF-α）结合的分离的结合蛋白，例如其抗体结合部分，例如人TNF-α，以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。
-
公开(公告)号：WO2011025964A2
公开(公告)日：2011-03-03
申请号：PCT/US2010/047006
申请日：2010-08-27
Applicant: ABBOTT LABORATORIES , BENATUIL, Lorenzo , BOGHAERT, Erwin, R. , GU, Jijie , HARRIS, Maria , HICKSON, Jonathan, A. , HSIEH, Chung-Ming , KUTSKOVA, Yuliya , LI, Yingchun , LIU, Zhihong , MORGAN-LAPPE, Susan
Inventor： BENATUIL, Lorenzo , BOGHAERT, Erwin, R. , GU, Jijie , HARRIS, Maria , HICKSON, Jonathan, A. , HSIEH, Chung-Ming , KUTSKOVA, Yuliya , LI, Yingchun , LIU, Zhihong , MORGAN-LAPPE, Susan
IPC: C07K16/28
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR移植抗体，人抗体和其DLL4结合片段，以高亲和力结合DLL4的蛋白，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，尤其用于治疗或预防肿瘤血管生成和/或其他血管生成依赖性疾病，例如眼新血管形成或以异常DLL4表达或活性为特征的血管生成非依赖性疾病，如自身免疫 包括多发性硬化症的疾病。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
